Arbutus Biopharma Corporation

Contributing Author

Recent Articles by Arbutus Biopharma Corporation

Nov-13	Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update ABUS -5.79% GlobeNewswire
Oct-07	Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting 2025 ABUS GlobeNewswire
Aug-06	Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update ABUS GlobeNewswire
Jun-25	Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus ABUS GlobeNewswire
May-14	Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update ABUS GlobeNewswire
May-07	Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025 ABUS GlobeNewswire